Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Quoc-Dien Trinh, M.D.

Co-Author

This page shows the publications co-authored by Quoc-Dien Trinh and Guru Sonpavde.
Connection Strength

1.712
  1. Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era? Urology. 2021 Jan; 147:199-204.
    View in: PubMed
    Score: 0.234
  2. Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2020 12; 18(6):e651-e659.
    View in: PubMed
    Score: 0.228
  3. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
    View in: PubMed
    Score: 0.210
  4. Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World J Urol. 2018 Nov; 36(11):1767-1774.
    View in: PubMed
    Score: 0.202
  5. The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17.
    View in: PubMed
    Score: 0.197
  6. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Aug; 95(2):251-63.
    View in: PubMed
    Score: 0.162
  7. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015 May; 94(2):228-37.
    View in: PubMed
    Score: 0.158
  8. Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. Urology. 2020 Jan; 135:44-49.
    View in: PubMed
    Score: 0.055
  9. Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU Int. 2019 07; 124(1):40-46.
    View in: PubMed
    Score: 0.053
  10. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019 05 01; 125(9):1449-1458.
    View in: PubMed
    Score: 0.052
  11. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2019 Oct; 37(10):2059-2065.
    View in: PubMed
    Score: 0.052
  12. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Mar; 93(3):257-76.
    View in: PubMed
    Score: 0.039
  13. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World J Urol. 2013 Feb; 31(1):5-11.
    View in: PubMed
    Score: 0.034
  14. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. Eur Urol. 2013 Feb; 63(2):371-8.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.